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C-fibers may modulate adjacent Aδ-fibers
through axon-axon CGRP signaling at
nodes of Ranvier in the trigeminal system
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Abstract
Background: Monoclonal antibodies (mAbs) towards CGRP or the CGRP receptor show good prophylactic
antimigraine efficacy. However, their site of action is still elusive. Due to lack of passage of mAbs across the blood-
brain barrier the trigeminal system has been suggested a possible site of action because it lacks blood-brain barrier
and hence is available to circulating molecules. The trigeminal ganglion (TG) harbors two types of neurons; half of
which store CGRP and the rest that express CGRP receptor elements (CLR/RAMP1).
Methods: With specific immunohistochemistry methods, we demonstrated the localization of CGRP, CLR, RAMP1,
and their locations related to expression of the paranodal marker contactin-associated protein 1 (CASPR). Furthermore,
we studied functional CGRP release separately from the neuron soma and the part with only nerve fibers of the
trigeminal ganglion, using an enzyme-linked immunosorbent assay.
Results: Antibodies towards CGRP and CLR/RAMP1 bind to two different populations of neurons in the TG and are
found in the C- and the myelinated Aδ-fibers, respectively, within the dura mater and in trigeminal ganglion (TG).
CASPR staining revealed paranodal areas of the different myelinated fibers inhabiting the TG and dura mater. Double
immunostaining with CASPR and RAMP1 or the functional CGRP receptor antibody (AA58) revealed co-localization of
the two peptides in the paranodal region which suggests the presence of the CGRP-receptor. Double immunostaining
with CGRP and CASPR revealed that thin C-fibers have CGRP-positive boutons which often localize in close proximity
to the nodal areas of the CGRP-receptor positive Aδ-fibers. These boutons are pearl-like synaptic structures, and we
show CGRP release from fibers dissociated from their neuronal bodies. In addition, we found that adjacent to the CGRP
receptor localization in the node of Ranvier there was PKA immunoreactivity (kinase stimulated by cAMP), providing
structural possibility to modify conduction activity within the Aδ-fibers.
Conclusion: We observed a close relationship between the CGRP containing C-fibers and the Aδ-fibers containing the
CGRP-receptor elements, suggesting a point of axon-axon interaction for the released CGRP and a site of action for
gepants and the novel mAbs to alleviate migraine.
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Introduction
The first drugs aimed directly at interfering with a
signaling pathway implicated in the pathophysiology of
migraine were recently approved by the FDA (Food and
Drug Administration) and EMA (European Medicines
Agency). These drugs specifically target the calcitonin
gene-related peptide (CGRP) signaling pathway [1, 2].
Although not all antimigraine drug candidates have
made it to the clinic, all drugs that inhibit CGRP signal-
ing have shown positive effects in all available trials to
date. These include drugs aborting acute attacks with
CGRP receptor antagonists (gepants) to prophylaxis
against chronic or frequent episodic migraine with
monoclonal antibodies (mAbs) against CGRP or the
CGRP receptor [1, 3, 4]. The highly effective CGRP/
CGRP receptor antibodies have not only given strong
evidence for the involvement of CGRP in migraine
pathophysiology, but in addition provided clues to
understand the mechanisms behind a migraine attack.
Since the mAbs i) do not cross the blood-brain bar-
rier (BBB) [5], and ii) there is no evidence for a leaky
BBB opening during an attack [6–8], the antimigraine
target must reside outside the central nervous system
(CNS).
Sensory neurons related to migraine pain are located
in the first division of the trigeminal ganglion (TG)
which is a part of the trigeminovascular system. The
presence of a large population of CGRP neurons within
the TG signifies a major role for CGRP in trigeminal
transmission [1, 9]. Immunohistochemistry with anti-
bodies against CGRP and in situ hybridization to localize
CGRP mRNA have shown that approximately half of all
neurons in the TG express CGRP [9]. CGRP is expressed
in unmyelinated C-fiber sensory nerves while the CGRP
receptor is expressed in myelinated Aδ-sensory nerves [9].
Recently Burstein and colleagues showed that cortical
spreading depression induced dilation and plasma pro-
tein extravasation were unaffected by the anti-CGRP
mAb, fremanezumab [10]. This study adds to their pre-
vious work, where they have postulated that the new
anti-migraine drugs may act to prevent CGRP binding
to trigeminal Aδ-fibers in the periphery [11]. Further-
more, with this in mind, we set out to further investigate
putative sites of CGRP action in the trigeminovascular
system, particularly in the TG, which we have hypothesized
to be the “tuner” for trigeminal pain [1, 12]. Further, these
interacting sites may be important for peripheral and/or
central sensitization, which are key modulators of pain
threshold in migraineurs. In vitro studies have shown that
CGRP can acutely modulate excitation in the somas of TG
[13, 14], but possible effects on the corresponding fibers
have received little interest. We hypothesize that CGRP
could modulate pain transmission through two pathways:
(i) regulation of excitatory potentials and signaling in TG
neuronal somas and/or (ii) modulation of conduction po-
tentials in TG sensory nerve fibers.
Saltatory conduction in myelinated axons such as Aδ-
sensory nerves involves distinct domains consisting of
the nodes of Ranvier along with the internodal, the jux-
taparanodal and the paranodal regions of the axon [15].
These domains arise from interactions between axons
and myelinating glial cells, mainly Schwann cells in the
peripheral nervous system (PNS) [16]. In addition, the
domains are known to have different compositions of
ion channels and therefore different physiological roles
[17, 18], e.g. a higher concentration of voltage-gated so-
dium channels are localized to the nodal region while
delayed rectifier potassium channels are mainly concen-
trated to the juxtaparanodal region as well as Schwann
cells.
Contactin-associated protein 1 (CASPR) is uniquely
localized to the paranodal regions during the onset of
myelination and this protein is a reliable marker for
axonal nodes [18, 19]. CASPR interacts with the glial ad-
hesion molecule Neurofascin-155 to anchor the Schwann
cell to the axon [18]. Therefore, we examined CGRP sig-
naling elements with respect to localization of CASPR to
test the hypothesis that nodes of Ranvier are a possible
target for modulation of conduction speed or potential
thresholds in trigeminal transmission.
Our study was designed to examine if there is possibil-
ity for crosstalk between sensory nerve fibers that is me-
diated by CGRP. With detailed neuroanatomical work
using a palette of selective antibodies we provide evi-
dence for a novel site of action on the Aδ-fibers for the
new CGRP receptor mAbs and the gepants.
Materials and methods
Immunohistochemistry
Male Wistar rats (n = 8, 260–300 g), raised and main-
tained under standard laboratory conditions (12/12 h
light-dark cycle, with dark beginning at 7 p.m.) were
used in this study. The animals were housed 2–3 rats to-
gether in Tall IVC Rat Cages (Innovive) with chow
(RM1, SDS) and water ad libitum. The experimental
procedures were approved by the Lund University
Animal Ethics Committee (M43–07) and performed in
accordance with the European Community Council Dir-
ective on ‘The Protection of Animals Used for Scientific
Purposes’ (2010/63/EU). The rats were anesthetized with
CO2 and decapitated, whereupon the right and left TG
where carefully removed as well as segments of dura
mater. The dura mater segments were spread out on
microscope slides (Superfrost, ThermoFisher), and allowed
to dry for approximately 15min.
The tissues were then fixated in 4% paraformaldehyde
(Sigma, St Louis, USA) diluted in phosphate buffered
saline (PBS) for 2–4 h. The fixated tissues were
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cryoprotected using first a 10% and then 25% sucrose
(Sigma) in Sorensen’s phosphate buffer overnight. Follow-
ing this, the TG was embedded in a gelatin medium (30%
egg albumin, 3% gelatin, Sigma) and subsequently cryosec-
tioned at 10 μm and stored at − 20 °C until use. The dura
mater slides were then stored in − 20 °C after cryoprotec-
tion (for treatment of whole mounts, see [20]).
The TG sections and dura mater slides where allowed
to thaw in room temperature and subsequently rehy-
drated and permeabilized in 0,25% Triton X-100 diluted
in PBS (PBS-T; Sigma) for 2 × 15 minutes. Primary anti-
bodies diluted in PBS-T containing 1% bovine serum
albumin (BSA; Sigma) were applied to the sections that
were then incubated at + 4 °C overnight. Sections were
subsequently rinsed of excess antibodies in PBS-T for
2 × 15 min. The sections were then incubated with sec-
ondary antibodies diluted in PBS-T for 1 h in a dark
room (details on antibodies can be found in Additional
file 3 Table S1 and Additional file 4 Table S2). Lastly,
excess secondary antibodies were rinsed with PBS-T 2 ×
15 min and the specimens mounted with anti-fading
medium (Vectashield, Vector laboratories, Burlingame,
CA, USA). The process was repeated with an additional
primary and secondary antibody before mounting when
performing double immunohistochemistry. Negative
controls followed the same procedure but in the absence
of primary antibodies.
Examination of the sections were performed using an
epifluorescence microscope (Nikon 80i, Tokyo, Japan)
coupled to a Nikon DS-2 MV camera. Images were ob-
tained using NIS basic research software (Nikon, Japan).
CGRP release
Six (n = 6) additional rats were anaesthetized by CO2 in-
halation and decapitated. These rats were housed in
Eurostandard cages (Type VI with 123-Lid) 2–6 to-
gether. The Danish Animal Experimentation Inspector-
ate approved all procedures. The protocol is described in
detail elsewhere [21, 22]. TGs were dissected and
immersed in 10ml synthetic interstitial fluid (SIF, com-
position: 108 mM NaCl, 3.5 mM KCl, 3.5 mM MgSO4,
26 mM NaHCO3, NaH2PO4, 1.5 mM CaCl2, 9.6 mM
NaGluconate, 5.6 mM glucose and 7.6 mM sucrose; pH
7.4.) at 37 °C for 30 min.
TGs were randomized, placed in Eppendorf tubes in a
heating block at + 37 °C. TGs were washed five times
(each wash 10 min), with 300 μl SIF. After 10 min incu-
bation with 300 μl SIF, 200 μl samples for measuring the
basal CGRP release were collected from the tissues,
mixed with 50 μl enzyme immunoassay buffer (contain-
ing protease inhibitors) and stored at − 20 °C until ana-
lysis, within a week after the experiment was performed.
The release of CGRP from TGs with soma and TGs
without soma was induced by 60mMK+-SIF. To
maintain equal osmolarity, Na+ was replaced with an
equimolar amount of K+ when making the depolarizing
buffer. Experiments by others have shown that 10 min
incubation is sufficient for a significant and reproducible
release of CGRP over basal levels (19). CGRP release
data point from the TG was excluded as the CGRP base-
line was 0 pg/ml.
The samples were processed using a commercial EIA
kit, Human CGRP ELISA KIT (SPIbio, Paris, France) to
study CGRP release. The protocol was performed follow-
ing the manufacturer’s instructions and the optical density
was measured at 410 nm using a micro-plate photometer
(Tecan, Infinite M200, software SW Magellan v.6.3,
Männedorf, Switzerland).
All quantitative data were analyzed using GraphPad
8.0, and are presented as mean ± SEM. The n indicates
the number of animals. The difference between the vari-
ables were compared with a two-sided paired Student’s
t-test, the data past the Shapiro-Wilks test for normality.
For art work, Servier Medical Art by Servier under a
Creative Commons 3.0 license was used.
Results
CGRP release from fiber-rich regions of the TG
In the TG, CGRP-containing C-fibers often run parallel
to Aδ-fibers that contain CGRP receptor elements [9].
Thus, we hypothesized that CGRP may have important
modulatory effects on the nerve fibers. In order for such
a hypothesis to be relevant, we needed to confirm that
CGRP could actually be released from the fiber itself and
not just from the neuronal soma. We therefore divided
the TG in two parts, one containing only nerve fibers
and one part containing soma with nerve fibers (Fig. 1).
Using a depolarization stimulus (60 mM K+-SIF), we in-
duced CGRP release from the nerve fibers themselves
(29.7 ± 4.5 pg/mL) as well as from the TG region con-
taining somas (46.4 ± 3.5 pg/mL). Interestingly, only
CGRP release from the somas could be inhibited with
sumatriptan (from 46.4 ± 3.5 pg/mL to 32.8 ± 2.3 pg/mL,
p = 0.012). No inhibition was seen in the nerve fiber seg-
ment (from 29.7 ± 4.5 pg/mL to 32.9 ± 4.6 pg/mL, p =
0.63). Thus, we demonstrated that CGRP could be re-
leased from both segments of the TG, but this release
could only be significantly inhibited with sumatriptan at
the soma segment.
Expression of CGRP receptors in nerve fibers
CGRP receptors were localized in larger neurons and
axonal fibers, consistent with myelinated Aδ sensory fi-
bers, as we have previously reported [23]. Since we dem-
onstrated that CGRP can be functionally released in a
part of the TG that only contains fibers, we further ex-
amined the expression of CGRP receptor targets in tri-
geminal fibers. We used a polyclonal antibody to CASPR
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as an immunofluorescent marker for nodes of Ranvier in
myelinated axons (Additional file 1 Figure 1). CASPR
immunoreactivity indicated a dense plexus of myelinated
fibers within the ganglion (Fig. 2). CASPR-positive stain-
ing showed a characteristic punctate doublet pattern that
reflects the location of this protein in the paranodal re-
gions (stained) on either side of the actual node (un-
stained) [16, 18]. We then used an antibody to RAMP1
(an integral protein of the CGRP receptor) to visualize
CGRP receptors in rat trigeminal ganglion (Fig. 2). Double
staining revealed co-localization of RAMP1 and CASPR
(Fig. 2) indicating CGRP receptors are discretely located
in the paranodal region of myelinated trigeminal axons.
Localization of CGRP receptors and PKA signaling in
trigeminal axons
Both the RAMP1 antibody (Fig. 3a) and the AA58 anti-
body (targeted to the functional CGRP receptor complex
[24], Fig. 3b), show that CGRP receptors specifically co-
localize with CASPR, indicating the receptor is present
in the paranodal region of the axon. Furthermore, the
AA58 antibody revealed that the functional CGRP recep-
tor was expressed in regions we suggest to be Schwann
cells (Fig. 3b). CGRP receptors are G-protein coupled re-
ceptors classically linked to Gs and increases in cyclic
AMP [25]. Evidence of relevant signaling pathways at
the nodes was indicated by positive staining for the cata-
lytic subunit of Protein Kinase A (PKA) which is acti-
vated by cAMP (Fig. 3c). Note, however, that while the
PKA catalytic subunit α is found in the axon around the
node region, it does not appear to co-localize with
CASPR. This suggests different subcellular locations for
the CGRP receptor and PKA within the axon [26], with
the receptor and CASPR being anchored to the membrane
whereas PKA is within the axon cytosol. This is similar to
what was observed for cytosolic endosomes labeled with
an Ab to EEA1 (early endosomal autoantigen 1)
(Additional file 2 Figure S2).
Fig. 1 CGRP release in vitro from two different regions isolated from the TG. The soma are located in the center of the TG (a). b The TG was cut
into one area that which is fiber-rich and devoid of neuronal cell bodies (“TG fibers”) and the other that was rich in neuronal somas (“TG soma”).
CGRP was increased significantly from baseline in all samples stimulated with 60mM K+ (** p > 0.01, *** p < 0.001, paired student’s T-test).
Sumatriptan significantly inhibited the CGRP release only from the from TG containing soma. Data is expressed as mean ± SEM, n = 6 for vehicle,
n = 5 for sumatriptan
Fig. 2 CGRP receptor localization at the paranodal region in the TGImmunohistochemical localization of the CGRP receptor protein RAMP1 (red,
arrow) in myelinated axons of the trigeminal ganglion labeled with CASPR (green, arrowhead), a marker for nodes of Ranvier. Merged images
reveal co-localization (yellow) of RAMP1 with CASPR at the nodes
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Relationship of CGRP-containing fibers with nodes on
myelinated axons in the TG
CGRP immunoreactivity was observed in smaller neu-
rons and thin C-fibers within the trigeminal ganglion.
There was no co-localization of CGRP with the nodal
marker CASPR. These findings are consistent with
CGRP localization in unmyelinated C-fibers and their
cell bodies and similar to what we have reported previ-
ously [23]. In the current study we observed that there is
often a close association between the thin and thick sen-
sory fibers (Fig. 4a). Higher magnifications of merged
images of CGRP and CASPR immunofluorescence show
CGRP-containing axonal varicosities, which are putative
release sites, align directly across from CASPR-positive
nodes of Ranvier along the adjacent myelinated axon
(Fig. 4b). These remarkable images suggest that the node
of Ranvier is a site of axon-axon communication where
CGRP released from C-fiber varicosities act on CGRP
receptors located within the nodes of Aδ-sensory nerves.
Localization of 5-hydroxytryptamine receptors in the TG
Since the triptans have proven successful as antimigraine
medication, we also investigated localization of the 5-
hydroxytryptamine (5-HT) receptors 5-HT1B and 5-
HT1D in TG neurons and fibers in relation to CASPR
(Fig. 5). In contrast to the CGRP receptor, neither 5-
HT1B nor 5-HT1D receptors showed specific co-
localization with CASPR. Immunoreactivity for 5-HT1B
and 5-HT1D was observed in TG axons. 5-HT1B and 5-
HT1D receptor immunoreactivities were also observed in
neuronal soma, satellite glial cells and Schwann cells.
These data match the results from the functional release,
as sumatriptan only inhibited CGRP release when the
TG preparation contained neuronal bodies (Fig. 1).
Peripheral nerve fibers in the dura mater
Since peripheral trigeminal afferents innervate the dura
mater, we examined the sensory nerves in this tissue.
Also in this preparation, the RAMP1 protein of the
CGRP receptor complex co-localized with CASPR
(Fig. 6a), further supporting a nodal location of the re-
ceptor. Sensory C- and Aδ-fibers characteristically run
together. Similar to what we found in the TG (Fig. 4),
there was a close relationship between CASPR positive
Aδ-fibers and CGRP positive C-fibers in the dura mater
(Fig. 6b). These findings suggest that CGRP axon-axon
signaling may occur along the entire trigeminal pathway,
both within the ganglion and along afferent projections.
Discussion
This is the first study to provide evidence for the innova-
tive hypothesis that axon-axon CGRP signaling occurs be-
tween C-fibers and the Aδ-fibers in the TG and in the
dura mater. These findings reveal a novel site where spe-
cific anti-migraine drugs may act to suppress trigeminal
pain transmission. The use of a CASPR antibody allowed
us to selectively visualize the nodes of Ranvier in sensory
Aδ-fibers and revealed the key, but unexpected, finding
Fig. 3 Localization of CGRP receptor and PKA at the nodes of Ranvier in trigeminal axons. CGRP receptors were labeled using a RAMP1 antibody
(a) or the AA58 antibody targeted to the functional CGRP receptor complex (b). Both antibodies showed co-localization with CASPR. Evidence of
relevant signaling pathways is indicated by positive staining for the catalytic subunit of Protein Kinase A (PKA) at the nodes (c). Arrows indicate
the node of Ranvier
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that CGRP receptors co-localize with CASPR. The nodes
of Ranvier are central to the process of salutatory conduc-
tion of axon potentials that underlies faster transmission
in myelinated nerves [27]. Modulation of ion channels
within the nodes could affect the threshold and rate of
nerve firing. The CASPR antibody also revealed a specific
pattern of nodes in close proximity to CGRP-positive
boutons on C-fibers. Furthermore, we demonstrated that
CGRP can be released from C-fibers in the TG. Together
these data suggest that CGRP regulates transmission in
trigeminal nerves via axon-axon signaling (Fig. 7). This
process may be an important mechanism in the patho-
physiology of migraine and may present a novel site of ac-
tion for anti-migraine drugs.
Fig. 5 Immunolocalization of 5-HT1B and 5-HT1D receptors in the TG. Green positive immunofluorescence for 5-HT1B (a) and 5-HT1D (b) receptors
throughout the Aδ-fiber, also at the node of Ranvier (monoclonal CASPR, red, arrow) No clear co-localization with CASPR was detected.
Arrowheads point out immunopositive axons for both receptors
Fig. 4 Immunolocalization of CGRP in rat trigeminal ganglia in relation to CASPR-positive axonal nodes. a The CGRP Ab labeled smaller neurons
and thin fibers (arrowhead) within the ganglia. Double staining with the CASPR Ab (arrow) showed no co-localization (merged). b Higher
magnification shows a CGRP-labeled axon in close proximity to CASPR-positive axons. CGRP-containing axonal varicosities (arrow), which are
putative release sites, align directly across from CASPR-positive nodes of Ranvier (arrowhead) on the adjacent axon
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CGRP as an axonal signaling molecule
CGRP release has previously been demonstrated in the
dura mater, the trigeminal nucleus caudalis (TNC) and
neuronal cell bodies in the trigeminal vascular system
[21, 28–30]. In the current study we show that CGRP
can be released directly from trigeminal nerve fibers in
response to depolarization. The thin, unmyelinated C-
fibers display a “pearl-like” pattern of CGRP-containing
varicosities at regular intervals along the nerve. These
varicosities, also referred to as “en-passant boutons”, are
characteristic of presynaptic release sites in peripheral
nerves [31]. There is a close association of C- and Aδ-
fibers within the TG, the trigeminal nerve and peripheral
targets such as the dura mater that suggests possible
CGRP signaling between the two types of pain fibers [9].
Remarkably, co-staining with CASPR and CGRP Abs
revealed that CGRP-labeled varicosities align closely
with nodes of Ranvier on Aδ-fibers that express CGRP
receptors. These structures are suggestive of axon-axon
synapses. To our knowledge, this mode of interaction
has not been reported before.
Possible mechanism of sensitization
The role of CGRP receptors located in the nodes of
Ranvier of Aδ-fibers remains speculative, however it
seems likely they are involved in modulating ion chan-
nels, sensitivity thresholds and/or nerve firing rates. The
CGRP receptor couples to a transmembrane G-protein
(Gαs) on the cytosolic side of the membrane. The Gαs
subunit activates adenylyl cyclase which in turn catalyzes
the conversion of ATP into the second messenger cyclic
AMP. Increasing cytosolic cyclic AMP concentration re-
sults in activation of protein kinase A (PKA), which we
found in the nodal region, and other intracellular path-
ways [32, 33]. Through kinase activation, CGRP could
regulate ion channels essential for nerve signal propaga-
tion [34–36] and contribute to mechanisms of neural
sensitization and/or increased intensity of pain transmis-
sion in migraine. Nodes of Ranvier are complex, highly
organized structures in which the central, unmyelinated
portion of the node itself is flanked by paranodal and
juxtaparanodal regions [15].
Gradation of the node and internode properties along
axons can tune conduction speed and activation thresh-
old [37]. This could occur by altering either the activity
of excitatory sodium channels or inhibitory potassium
channels. We focus here on excitatory activation. A
possible mechanism of pain generation by K+-channels
has been discussed elsewhere [12]. The node of
Ranvier contains voltage-gated sodium channels (NaV)
such as NaV1.6 and NaV1.1 [38], while voltage-gated
potassium channels (KV) are localized to the juxtapar-
anodal region [39, 40].
Individual anatomical parameters of myelinated axons
can be tuned to optimize pathways involved in temporal
processing. For example, additional NaV channels such
as NaV1.7 (expressed at nodes of Ranvier in a subpopu-
lation of Aδ-fibers within sciatic nerve and dorsal root
ganglion, DRG) has been shown to modulate pain per-
ception in animal models [41, 42]. These observations
are consistent with critical roles for NaV1.7 channels at
multiple sites within nociceptive DRG neurons and their
processes [43]. It has further been suggested that during
neuropathic pain (in the DRG), an increase in cyclic
AMP would induce a negative shift of the activation of
sodium currents. The action potential threshold would
Fig. 6 Expression of RAMP1 and CGRP in relation to the node of Ranvier in rat dura mater spreads. RAMP1 (a) and CGRP (b) had similar
localization at the node of Ranvier in the rat dura mater as for the TG. Top; CASPR (green, arrowhead), RAMP1 (red, arrow). Bottom; CASPR (green,
arrowhead), CGRP (red, arrow)
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thus decrease and neuronal hyperexcitability would in-
crease [44].
We postulate that similar activation by nodal CGRP
receptors could occur in migraine patients.
In addition to being a potential target for the current
drugs targeting the CGRP receptor or CGRP release, we
questioned if other anti-migraine drugs also target
axonal nodes and possible interactions of C- and Aδ-
fibers. The current mechanism of action of triptans,
ditans and potentially new anti-migraine compounds,
e.g. agonists aimed at the P2Y13 receptor, have been
linked to inhibiting CGRP release through receptors
coupling to Gi proteins [12, 22, 45, 46]. In the current
paper, we show an effect of triptans in TG regions that
contain neuronal cell bodies, but not in fiber-rich areas
devoid of somas. These data offer an explanation to why
for example sumatriptan does not fully inhibit CGRP re-
lease in previous studies from the TG [30] but has a full
effect on isolated TG neurons [29].
Site of action for anti-migraine drugs
The effectiveness of mAbs targeting CGRP or its recep-
tor indicates that their site of action must be in the per-
iphery as the mAbs do not cross the BBB [5]. Triptans
are also considered to have little to no ability to cross
the BBB [47]. Moreover, there is no evidence that the
BBB is altered during a migraine attack [6–8]. Currently,
hypothesized drug targets include trigeminal neuron
synapses, neuronal somas in the TG, or the synapses lo-
calized in the TNC [1, 2, 11, 12]. The role of Aδ-fibers
in migraine pathology was recently strengthen by the
work of Burstein and colleagues which concluded that
Fig. 7 Schematic overview of the possible modulation by C-fibers on adjacent Aδ-fibers through axon-axon signaling at nodes of Ranvier in the
trigeminal system. CGRP is released from the C-fiber bouton and diffuses into the node of Ranvier. Activation of the CGRP receptor causes
increase in cyclic AMP, which could alter the conductivity of Na+ or K+ channels through Phosphokinase A (PKA). Furthermore, there is a
possibility that 5-HT receptors could negatively modulate the cyclic AMP at the node. Alterations in Na+ or K+ channels could modulate the
nodal threshold of activation. The schematic also includes a hypothesis on the mode of action of the anti-migraine antibody treatments
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dilation and plasma protein extravasation induced by
cortical spreading depression are unaffected by the anti-
CGRP mAb; Fremanezumab [10]. Therefore, the most
likely target of CGRP released in migraine is the Aδ-
fibers. The current study indicates a potential specific
and novel target located on the Aδ-fiber, namely axo-
axonal synapses between the C-fibers and Aδ-fibers and
suggests that such interactions can occur along the sen-
sory fibers, altering sensory processing.
The TG is outside the BBB [48, 49], however the ques-
tion arises as to whether the nodes of Ranvier would be
accessible to anti-migraine Abs. It has been shown that
the node of Ranvier is indeed permeable to both smaller
and larger water-soluble molecules. Miezwa and col-
leagues have investigated this in depth, using 3 kDa and
70 kDa dextran tracers coupled to fluorescein, which is
comparable to the size of CGRP (5 kDa) and the size of
the mAbs (150 kDa). Both 3 and 70 kDa tracers are able
to penetrate from the perinodal space symmetrically into
the paranodes on either side of the node of Ranvier at a
rate consistent with diffusion through an elongated
helical pathway between the paranodal terminal loops of
the myelin sheath. Hence, it appears likely that CGRP
receptors within the node of Ranvier are an accessible
drug target [50].
Conclusion and perspective
To our knowledge, this is the first study to provide evi-
dence for axon-axon synapses between adjacent sensory
nerve fibers. Use of an Ab to the nodal marker CASPR
was instrumental in clarifying the relationship of nodal
CGRP receptors in Aδ-fibers to CGRP release sites in
varicosities in C-fibers. While more needs to be learned,
the ability of CGRP to regulate the excitability of trigem-
inal fibers via the nodes of Ranvier would be a significant
mechanism in modulating pain transmission. This
mechanism would likely contribute to migraine head-
ache pathology and provide a novel target for anti-
migraine drugs.
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